AdvanCell
Cambridge, US · Founded 2026 · Delaware corporation · 99 employees on LinkedIn · 9 known investors
Find your way into AdvanCell
793 people in our graph share verified history with the AdvanCell team — schools, employers, funds. One of them is your warm intro.
Vidu Shanmugarajahunlockedknows Aaron Pickett · together at Allen & Overy (overlapped)
×6knows the team · via University of California, Berkeley
×4knows the team · via Phillips Academy
knows the team · via Australian Institute of Company Directors
AdvanCell is a clinical-stage radiopharmaceutical company developing a pipeline of targeted alpha therapies for the treatment of cancers including prostate, melanoma, ovarian, breast, and lung. Its lead-212-based programs, such as ADVC001 for metastatic prostate cancer, are in clinical development.
Founders & leadership
AdvanCell was founded in 2026 by Andrew Adamovich.
AA
Andrew AdamovichinFounder & Managing Director, AustraliaAndrew Adamovich is Director at AdvanCell, a clinical-stage radiopharmaceutical company developing targeted alpha therapies for cancer treatment. He has prior experience in venture capital and private equity, with expertise in corporate development and mergers and acquisitions.
PL
Philina LeeinChief Executive Officer
AP
Aaron PickettinHead of Legal & HR, Company SecretaryAaron Pickett is Executive Officer overseeing legal and HR functions at AdvanCell, a clinical-stage radiopharmaceutical company developing targeted alpha therapies for cancer treatment. He previously spent over nine years as General Counsel at GenesisCare and worked at law firms including Allen & Overy, Herbert Smith Freehills, and MinterEllisonRuddWatts, with expertise in mergers and acquisitions, capital offerings, and healthcare regulation.
Board
WC
Wing Cheong LamBoard director
NE
Nik EconomopoulosBoard director
AA
Anthony AiudiBoard director
BM
CG
KC
Kevin CameronBoard director
AK
Andrew KayBoard director
Investors · 9
Bain Capital Life SciencesBoston
Catalio Capital Management, LPNew York
Proto AxiomSydney
SV Health InvestorsBoston · $1M – $20M
Tenmile
AbingworthreportedLondon · $15M – $30Mvia Bali Muralidhar · board
Ally Bridge Groupreported · 2 sourcesNew York
Sanofi VenturesreportedCambridge · $5M
T. Rowe PricereportedBaltimore
Funding
SEC filings, press & company announcements$533.3M disclosed across 2 rounds · 2026
- $315MSeries DJul 2026Source ↗
▶$218.3MraisedJul 2026 · 41 investors · BiotechnologyRule 506(b)
AdvanCell has filed a notice of an exempt offering of securities to raise $315 Million in New Funding. - intelligence360intelligence360.news · Aug 2026
AdvanCell Closes US $315 Million Oversubscribed Series D Financing to Advance Targeted Alpha Therapies and Expand Clinical and Commercial Manufacturing Infrastructurebusinesswire.com · Jul 2026 · press release
▶$218.3MraisedJul 2026 · 41 investors · Biotechnology
Rule 506(b)AdvanCell has filed a notice of an exempt offering of securities to raise $315 Million in New Funding. - intelligence360intelligence360.news · Aug 2026Officers, directors & promoters on the filing
- Philina LeeExecutive Officer, Director
- Aaron PickettExecutive Officer
- Wing Cheong LamDirector
- Nik EconomopoulosDirector
- Anthony AiudiDirector
- Bali MuralidharDirector
- Jamil BegDirector
- Christopher GagliardiDirector
- Andrew AdamovichDirector
- Andrew KayDirector
- Kevin CameronDirector
- Offering amount
- $315M
- Amount sold
- $218.3M
- First sale
- Jun 2026
- Incorporated
- Corporation, Delaware, 2026
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlap
AvenCell9 shared keywordsAvenCell Therapeutics develops next-generation cell therapies for hard-to-treat cancers, including solid tumors, combining switchable universal CAR-T technology with a CRISPR/Cas9-based allogeneic platform. The clinical-stage biopharmaceutical company creates autologous and allogeneic reprogrammable T-cell products and operates in both the US and Europe.
Applied StemCell6 shared keywordsApplied StemCell is a genome engineering platform company that develops proprietary technologies and iPSC expertise to enable safe, scalable integration of large DNA payloads into the mammalian genome for gene and cell-based medicine. The company provides end-to-end solutions for academia and biopharma partners to accelerate therapeutic development.
Companies competing with AdvanCell for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
The 19 Largest Global Startup Funding Rounds of July 2026 – AlleyWatchalleywatch.com · Aug 2026AdvanCell has filed a notice of an exempt offering of securities to raise $315 Million in New Funding. - intelligence360intelligence360.news · Aug 2026Frequently asked questions
- What does AdvanCell do?
- AdvanCell is a clinical-stage radiopharmaceutical company developing a pipeline of targeted alpha therapies for the treatment of cancers including prostate, melanoma, ovarian, breast, and lung. Its lead-212-based programs, such as ADVC001 for metastatic prostate cancer, are in clinical development.
- Who founded AdvanCell?
- AdvanCell was founded by Andrew Adamovich in 2026.
- Who are AdvanCell's investors?
- AdvanCell's investors include Bain Capital Life Sciences, Catalio Capital Management, LP, Proto Axiom, SV Health Investors, Tenmile, Abingworth, Ally Bridge Group, Sanofi Ventures and 1 more.
- How much funding has AdvanCell raised?
- AdvanCell has disclosed $533.3M raised across 2 rounds.
- Where is AdvanCell headquartered?
- AdvanCell is headquartered in Cambridge, US.